Filing Flows › Immucell (ICCC) › Q4 2024
Immucell (ICCC) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 28, 2025
Immucell (ICCC) reported revenue of $7.8M for the fourth quarter 2024 (Q4 2024), +52% from a year earlier and +29% from the quarter before. Operating margin was 8.0%, net earnings $515K (6.6% of revenue).
Immucell, Q4 2024: revenue $7.8M (+52% year over year), operating margin 8.0%, net earnings $515K, operating cash flow −$3K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.8M | +29% | +52% |
| Gross profit | $2.8M | +79% | +125% |
| Operating profit | $621K | — | — |
| Net earnings | $515K | — | — |
| Operating cash flow | −$3K | — | — |
What changed
Revenue was $7.8M in Q4 2024, up 52% year over year and up 29% from the previous quarter. First Defense Product Line was the largest line at 99% of revenue.
Gross margin was 36.5%, up 11.9 points from a year earlier. Operating profit was $621K, a 8.0% margin (up 27.7 points year over year). Operating expenses fell 2% while revenue rose 52%. The fastest-growing cost line was Sales & marketing (+25%). Net earnings were $515K. The effective tax rate was 1.2%.
Operating cash flow was −$3K. Non-cash charges added back $685K of depreciation and amortization and $69K of share-based compensation. Working capital and other items used $1.3M. Capital expenditures of $196K exceeded it, leaving free cash flow of −$199K.
Questions
What was Immucell's revenue in the fourth quarter 2024?
Immucell (ICCC) reported revenue of $7.8M for the fourth quarter 2024 (Q4 2024), +52% from a year earlier and +29% from the quarter before.
Was Immucell profitable in the fourth quarter 2024?
Operating profit was $621K (8.0% of revenue) and net earnings $515K.
Source: Immucell 10-K on SEC EDGAR.